|Day's Range||0.000 - 0.000|
|52 Week Range|
|PE Ratio (TTM)||22.78|
|Dividend & Yield||1.03 (3.16%)|
|1y Target Est||N/A|
While the Republican-led Congress continues the push to repeal the Affordable Care Act, we still see challenges in passing any new legislation.
Roche (RHHBY) announced that the FDA has granted approval to the subcutaneous injection of its marketed lymphoma drug MabThera/Rituxan as Rituxan Hycela for the treatment of adults with different types of blood cancers.
The Zacks Analyst Blog Highlights: Novartis, Roche, Shire, Neos and Novo Nordisk